Companies Unicycive Therapeutics, Inc.
Unicycive Therapeutics (UNCY): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Unicycive Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,044,062FY2023
- $2,439,884FY2024
- $2,391,621FY2025
CEO total pay was $2,391,621 in fiscal 2025, down from $2,439,884 in fiscal 2024.
FY2025: salary $572,000 · bonus $486,200 · stock awards $0 · option awards $1,333,421
Order UNCY
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Shalabh Gupta | $572,000 | $486,200 | $0 | $1,333,421 | $0 | $0 | — | $2,391,621 |
| Chief Executive Officer | ||||||||
| Doug Jermasek | 363,000 | 77,138 | 0 | 41,028 | 0 | 0 | — | 481,166 |
| Executive VP, Corporate Strategy | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Shalabh Gupta | $2,391,621 | $2,439,884 | $4,044,062 | ↓ −48,263 |
| Doug Jermasek | 481,166 | 873,346 | 1,267,854 | ↓ −392,180 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee recommends to the Board for approval the overall compensation philosophy for the company and periodically reviews it to ensure it is appropriate and does not incentivize unnecessary and excessive risk taking. Executive compensation consists of base salary, annual discretionary bonuses based on performance objectives, and equity-based compensation awards.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Shalabh Gupta | Option | 642 | 7.5 | — |
| Doug Jermasek | Option | 1,261 | 7.5 | — |
| Shalabh Gupta | Option | 1,971 | 7.5 | — |
| Shalabh Gupta | Option | 5,450 | 3.4 | — |
| Doug Jermasek | Option | 5,450 | 3.4 | — |
| Doug Jermasek | Option | 10,000 | 4.71 | — |
| Shalabh Gupta | Option | 15,526 | 3.4 | — |
| Shalabh Gupta | Option | 27,024 | 11.4 | — |
| Doug Jermasek | Option | 27,024 | 11.4 | — |
| Shalabh Gupta | Option | 42,344 | 7.5 | — |
| Doug Jermasek | Option | 42,344 | 7.5 | — |
| Shalabh Gupta | Option | 76,977 | 11.4 | — |
| Shalabh Gupta | Option | 90,000 | 4.71 | — |
| Shalabh Gupta | Option | 146,400 | 7.5 | — |
| Shalabh Gupta | Option | 325,000 | 4.71 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gaurav Aggarwal, M.DIndependent · Audit · Compensation (Chair) · Nominating and Governance · Departed during FY | $65,000 | $0 | $84,486 | — | — | $149,486 |
| Saraswati Kenkare-Mitra, Ph.DIndependent · Audit · Compensation · Nominating and Governance (Chair) | 63,000 | 0 | 84,486 | — | — | 147,486 |
| Shalabh Gupta, M.DEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $50,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $128,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $128,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Unicycive Therapeutics as a peer
Companies that benchmark against UNCY
No companies currently name UNCY as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Unicycive Therapeutics, Inc. | 2025 | Shalabh Gupta | $572,000 | $0 | $1,333,421 | $0 | $2,391,621 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (8 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Shalabh Gupta. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 2,391,621. View filing ↗
- Section 01, Doug Jermasek. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 481,166. View filing ↗
- Section 08, Gaurav Aggarwal, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 149,486. View filing ↗
- Section 08, Saraswati Kenkare-Mitra, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 147,486. View filing ↗
- Section 08, Shalabh Gupta, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 128,000 + equity 0 + all other 0 = 128,000, summed across the director compensation table rows.
- Unicycive Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Unicycive Therapeutics, Inc.'s own proxy. As printed: 2,391,621. View filing ↗